Basilea reports granting of U.S. orphan drug designation to isavuconazole for the treatment of invasive candidiasis

In continuation of my up date on isavuconazole

Isavuconazole (BAL4815) is an experimental triazole antifungal. Its prodrug, isavuconazonium sulfate (BAL8557) is currently in two Phase III clinical trials (SECURE and VITAL), the results of which are expected in the second half of 2013. 

Basilea Pharmaceutica Ltd. reports today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to isavuconazole for the treatment of invasive candidiasis/candidemia, a potentially life-threatening infection caused by Candida yeasts. Isavuconazole has previously been granted orphan drug status in the European Union and the U.S. for the treatment of invasive aspergillosis and mucormycosis.

Basilea reports granting of U.S. orphan drug designation to isavuconazole for the treatment of invasive candidiasis